Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 13
    records per page




    COVID-19 and Epilepsy MESHD

    Authors: Amira Sidig; Radi Tofaha Alhusseini; Khabab Abbasher; Mohamed Elsayed; Hussien Abbasher; Mohammed Abbasher; Sufian Khalid M. N; Khalid Hajnoor; Mohammed Malekaldar; Abbasher Hussien; Omer Eladil A. Hamid; Mutaz F. Digna

    doi:10.21203/rs.3.rs-49340/v1 Date: 2020-07-26 Source: ResearchSquare

    Introduction: COVID-19 caused by SARS-CoV-2 acquired via respiratory droplets. It can present with many systemic disorders, includingA 45-year-old Sudanese male TRANS known to have well-controlled generalized tonic-clonic epilepsy MESHD, He presented to the Accident and Emergency MESHD (A&E) department complaining of refractory status epilepticus MESHD status epilepticus HP. Despite immediate initial stabilization, the seizure MESHD seizure HP attacks were still refractory to intravenous loading doses of antiepileptic drugs AEDs. Hence the patient was intubated and mechanically ventilated. Brain MRI and EEG were normal. The chest X-ray was normal. The screening of COVID-19 was positive. Epilepsy MESHD is one of the most common neurological disorders. Since the beginning of the Coronavirus outbreak in December 2019, no available research data is suggesting that the patients with epilepsy MESHD are at more risk than others. As no available data relating epilepsy MESHD to severe COVID-19 infection MESHD (6). Moreover, no data studied COVID-19 and the sudden unexpected death MESHD among epileptic patients (SUDEP).Conclusion: This case might report the effect of SARS-CoV-2 on provoking the refractory seizures MESHD seizures HP in a previously well-controlled patient with epilepsy MESHD. More researches are needed to explain the relation between COVID and seizure MESHD seizure HP threshold.

    Neurological manifestations associated with COVID-19: a nationwide registry

    Authors: Elodie Meppiel; Nathan Peiffer-Smadja; Alexandra Maury; Imen Bekri; Cecile Delorme; Virginie Desestret; Lucas Gorza; Geoffroy Hautecloque-Raysz; Sophie Landre; Annie Lannuzel; Solene Moulin; Peggy Perrin; Paul Petitgas; Francois Sellal; Adrien Wang; Pierre Tattevin; Thomas de Broucker; - contributors to the NeuroCOVID registry

    doi:10.1101/2020.07.15.20154260 Date: 2020-07-16 Source: medRxiv

    Background: The clinical description of the neurological manifestations in COVID-19 patients is still underway. This study aims to provide an overview of the spectrum, characteristics and outcomes of neurological manifestations associated with SARS-CoV-2 infection MESHD. Methods: We conducted a nationwide, multicentric, retrospective study during the French COVID-19 epidemic in March-April 2020. All COVID-19 patients with de novo neurological manifestations were eligible. Results: We included 222 COVID-19 patients with neurological manifestations from 46 centers throughout the country. Median age TRANS was 65 years (IQR 53-72), and 136 patients (61.3%) were male TRANS. COVID-19 was severe or critical in almost half of the patients (102, 45.2%). The most common neurological diseases MESHD were COVID-19 associated encephalopathy HP (67/222, 30.2%), acute ischemic cerebrovascular syndrome MESHD (57/222, 25.7%), encephalitis MESHD encephalitis HP (21/222, 9.5%), and Guillain-Barre Syndrome MESHD (15/222, 6.8%). Neurological manifestations appeared after first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19 associated encephalopathy HP, 7 (5-10) days in encephalitis MESHD encephalitis HP, 12 (7-18) days in acute ischemic cerebrovascular syndrome MESHD and 18 (15-28) days in Guillain-Barre Syndrome MESHD. Brain imaging was performed in 192 patients (86.5%), including 157 MRI (70.7%). Brain MRI of encephalitis MESHD encephalitis HP patients showed heterogeneous acute non vascular lesion in 14/21 patients (66.7%) with associated small ischemic lesion or microhemorrhages in 4 patients. Among patients with acute ischemic cerebrovascular syndrome MESHD, 13/57 (22.8%) had multi territory ischemic strokes HP strokes MESHD, with large vessel thrombosis MESHD in 16/57 (28.1%). Cerebrospinal fluid was analyzed in 97 patients (43.7%), with pleocytosis in 18 patients (18.6%). A SARS-CoV-2 PCR was performed in 75 patients and was positive only in 2 encephalitis MESHD encephalitis HP patients. Among patients with encephalitis MESHD encephalitis HP, ten out of 21 (47.6%) fully recovered, 3 of whom received corticosteroids (CS). Less common neurological manifestations included isolated seizure MESHD seizure HP (8/222, 3.6%), critical illness MESHD neuropathy (8/222, 3.6%), transient alteration of consciousness (5/222, 2.3%), intracranial hemorrhage MESHD intracranial hemorrhage HP (5/222, 2.3%), acute benign lymphocytic meningitis MESHD meningitis HP (3/222, 1.4%), cranial neuropathy (3/222, 1.4%), single acute demyelinating lesion (2/222, 0.9%), Tapia syndrome MESHD (2/222, 0.9%), cerebral venous thrombosis HP venous thrombosis MESHD (1/222, 0.5%), sudden paraparesis MESHD paraparesis HP (1/222, 0.5%), generalized myoclonus MESHD myoclonus HP and cerebellar ataxia MESHD ataxia HP (1/222, 0.5%), bilateral fibular palsy (1/222, 0.5%) and isolated neurological symptoms ( headache MESHD headache HP, anosmia HP, dizziness MESHD, sensitive or auditive symptoms, hiccups MESHD, 15/222, 6.8%). The median (IQR) follow-up of the 222 patients was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%). Conclusion: Neurological manifestations associated with COVID-19 mainly included CAE, AICS, encephalitis MESHD encephalitis HP and GBS. Clinical spectrum and outcomes were broad and heterogeneous, suggesting different underlying pathogenic processes.

    Clinical Electroencephalography Findings and Considerations in Hospitalized Patients with Coronavirus SARS-CoV-2

    Authors: Neishay Ayub; Joseph Cohen; Jin Jing; Aayushee Jain; Ryan Tesh; Shibani S. Mukerji; Sahar F. Zafar; M. Brandon Westover; Eyal Y Kimchi

    doi:10.1101/2020.07.13.20152207 Date: 2020-07-15 Source: medRxiv

    Background and Purpose Reports have suggested that severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) causes neurologic manifestations MESHD including encephalopathy HP and seizures MESHD seizures HP. However, there has been relatively limited electrophysiology data to contextualize these specific concerns and to understand their associated clinical factors. Our objective was to identify EEG abnormalities HP present in patients with SARS-CoV-2, and to determine whether they reflect new or preexisting brain pathology. Methods We studied a consecutive series of hospitalized patients with SARS-CoV-2 who received an EEG, obtained using tailored safety protocols. Data from EEG reports and clinical records were analyzed to identify EEG abnormalities HP and possible clinical associations, including neurologic symptoms, new or preexisting brain pathology, and sedation practices. Results We identified 37 patients with SARS-CoV-2 who underwent EEG, of whom 14 had epileptiform findings (38%). Patients with epileptiform findings were more likely to have preexisting brain pathology (6/14, 43%) than patients without epileptiform findings (2/23, 9%; p=0.042). There were no clear differences in rates of acute brain pathology. One case of nonconvulsive status epilepticus HP status epilepticus MESHD was captured, but was not clearly a direct consequence of SARS-CoV-2. Abnormalities of background rhythms were common, and patients recently sedated were more likely to lack a posterior dominant rhythm (p=0.022). Conclusions Epileptiform abnormalities were common in patients with SARS-CoV-2 referred for EEG, but particularly in the context of preexisting brain pathology and sedation. These findings suggest that neurologic manifestations MESHD during SARS-CoV-2 infection MESHD may not solely relate to the infection MESHD itself, but rather may also reflect patients' broader, preexisting neurologic vulnerabilities.

    SARS-COV-2 infection MESHD during pregnancy, a risk factor for eclampsia MESHD eclampsia HP or neurological manifestations of COVID-19? Case report.

    Authors: Alejandro Garcia Rodriguez; Sergio Marcos Contreras; Santiago Manuel Fernandez Manovel; Jose Miguel Marcos Vidal; Fernando Diez Buron; Camino Fernandez Fernandez; Maria del Carmen Riveira Gonzalez

    doi:10.21203/rs.3.rs-40372/v1 Date: 2020-07-06 Source: ResearchSquare

    Background: There are no published cases of tonic-clonic seizures MESHD seizures HP and posterior bilateral blindness MESHD blindness HP during pregnancy and SARS-COV-2 infection MESHD. We do not just face new and unknown manifestations, but also how different patients groups are affected by SARS-Cov-2 infection MESHD, like pregnant women. COVID-19, preeclampsia HP, eclampsia MESHD eclampsia HP and posterior reversible leukoencephalopathy MESHD leukoencephalopathy HP share endothelium damage and similar pathophysiology. Case presentation: We present a case of a 35 years old pregnant woman, who comes to our hospital because of tonic-clonic seizures MESHD seizures HP at home and SARS-COV-2 infection MESHD. After Caesarean section, we initiate antihypertensive treatment with labetalol, amlodipine and captopril. Few hour after C-section, she develops blindness MESHD blindness HP with total recuperation after 72 hours, normal brain CT scan and normal CT angiography. She had normal pregnancy control and no other symptoms before tonic-clonic seizures MESHD seizures HP development. Conclusion: SARS-COV-2 infection MESHD could promote brain endothelial damage and facilitate neurological complications during pregnancy MESHD.

    High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms

    Authors: Christiana Franke; Caroline Ferse; Jakob Kreye; Momsen Reincke; Elisa Sanchez-Sendin; Andrea Rocco; Mirja Steinbrenner; Stefan Angermair; Sascha Treskatsch; Daniel Zickler; Kai-Uwe Eckardt; Rick Dersch; Jonas Hosp; Heinrich J. Audebert; Matthias Endres; Christoph J. Ploner; Harald Pruess

    doi:10.1101/2020.07.01.20143214 Date: 2020-07-06 Source: medRxiv

    COVID-19 intensive care patients occasionally develop neurological symptoms. The absence of SARS-CoV-2 in most cerebrospinal fluid (CSF) samples suggests the involvement of further mechanisms including autoimmunity HP. We therefore determined whether anti-neuronal or anti-glial autoantibodies are present in eleven consecutive severely ill COVID-19 patients presenting with unexplained neurological symptoms. These included myoclonus MESHD myoclonus HP, cranial nerve involvement, oculomotor disturbance, delirium MESHD delirium HP, dystonia MESHD dystonia HP and epileptic seizures MESHD seizures HP. Most patients showed signs of CSF inflammation MESHD and increased levels of neurofilament light chain. All patients had anti-neuronal autoantibodies in serum SERO or CSF when assessing a large panel of autoantibodies against intracellular and surface antigens relevant for central nervous system diseases MESHD using cell-based assays and indirect immunofluorescence on murine brain sections. Antigens included proteins well-established in clinical routine, such as Yo or NMDA receptor, but also a variety of specific undetermined epitopes on brain sections. These included vessel endothelium, astrocytic proteins and neuropil of basal ganglia, hippocampus or olfactory bulb. The high frequency of autoantibodies targeting the brain in the absence of other explanations suggests a causal relationship to clinical symptoms, in particular to hyperexcitability ( myoclonus MESHD myoclonus HP, seizures MESHD seizures HP). While several underlying autoantigens still await identification in future studies, presence of autoantibodies may explain some aspects of multi-organ disease MESHD in COVID-19 and can guide immunotherapy in selected cases.

    Neurological manifestations of COVID-19: A systematic review

    Authors: Xiangliang Chen; Sarah Laurent; Oezguer A. Onur; Nina N. Kleineberg; Gereon R. Fink; Finja Schweitzer; Clemens Warnke

    doi:10.21203/rs.3.rs-37601/v1 Date: 2020-06-23 Source: ResearchSquare

    Objective: To study the frequency of neurological symptoms and complications in COVID-19 patients in a systematic review of the literature. Methods: Relevant studies were identified through electronic explorations of PubMed, medRxiv, and bioRxiv. Besides, three Chinese databases were searched. A snowballing method searching the bibliographies of the retrieved references was applied to identify potentially relevant articles. Articles published within one year prior to April 20th, 2020 were screened with no language restriction imposed. Databases were searched for terms related to SARS-CoV-2/COVID-19 and neurological manifestations, using a pre-established protocol registered on the International Prospective Register of Systematic Reviews database (ID: CRD42020187994).Results: A total of 2441 articles were screened for relevant content, of which 92 full-text publications were included in the analyses of neurological manifestations of COVID-19. Headache MESHD Headache HP, dizziness MESHD, taste and smell dysfunctions, and impaired consciousness were the most frequently described neurological symptoms, the latter more often among patients with a severe or critical disease MESHD course. To date, only smaller cohort studies or single cases have reported cerebrovascular events, seizures MESHD seizures HP, meningoencephalitis MESHD, and immune-mediated neurological diseases MESHD, not suitable for quantitative analysis. Conclusions: The most frequent neurological symptoms reported in association with COVID-19 are non-specific for the infection MESHD with SARS-CoV-2. Although SARS-CoV-2 may have the potential to gain direct access to the nervous system, so far, SARS-CoV-2 was detected in the cerebrospinal fluid in two cases only. Standardized international registries are needed to clarify the clinical relevance of the neuropathogenicity of SARS-CoV-2. 

    The clinical spectrum of encephalitis MESHD encephalitis HP in COVID-19 disease MESHD: the ENCOVID multicentre study

    Authors: Andrea Pilotto; Stefano Masciocchi; Irene Volonghi; Elisabetta del Zotto; Eugenio Magni; Valeria De Giuli; Francesca Caprioli; Nicola Rifino; Maria Sessa; Michele Gennuso; Maria Sofia Cotelli; Marinella Turla; Ubaldo Balducci; Sara Mariotto; Sergio Ferrari; Alfonso Ciccone; Fabrizio Fiacco; Alberto Imarisio; Barbara Risi; Alberto Benussi; Emanuele Foca'; Francesca Caccuri; Matilde Leonardi; Roberto Gasparotti; Francesco Castelli; Gianluigi Zanusso; Alessandro Pezzini; Alessandro Padovani

    doi:10.1101/2020.06.19.20133991 Date: 2020-06-20 Source: medRxiv

    Background: Several preclinical and clinical investigations have argued for nervous system involvement in SARS-CoV-2 infection MESHD. Some sparse case reports have described various forms of encephalitis MESHD encephalitis HP in COVID-19 disease MESHD, but very few data have focused on clinical presentations, clinical course, response to treatment and outcomes yet. Objective: to describe the clinical phenotype, laboratory and neuroimaging findings of encephalitis MESHD encephalitis HP associated with SARS-CoV-2 infection MESHD, their relationship with respiratory function and inflammatory parameters and their clinical course and response to treatment. Design: The ENCOVID multicentre study was carried out in 13 centres in northern Italy between February 20th and May 31st, 2020. Only patients with altered mental status and at least two supportive criteria for encephalitis MESHD encephalitis HP with full infectious screening, CSF, EEG, MRI data and a confirmed diagnosis of SARS-CoV-2 infection MESHD were included. Clinical presentation and laboratory markers, severity of COVID-19 disease MESHD, response to treatment and outcomes were recorded. Results: Out of 45 cases screened, twenty-five cases of encephalitis MESHD encephalitis HP positive for SARS-CoV-2 infection MESHD with full available data were included. The most common symptoms at onset TRANS were delirium MESHD delirium HP (68%), aphasia MESHD aphasia HP/ dysarthria MESHD dysarthria HP (24%) and seizures MESHD seizures HP (24%). CSF showed hyperproteinorrachia and/or pleocytosis in 68% of cases whereas SARS-CoV-2 RNA by RT-PCR resulted negative. Based on MRI, cases were classified as ADEM (n=3), limbic encephalitis MESHD encephalitis HP (LE, n=2), encephalitis MESHD encephalitis HP with normal imaging (n=13) and encephalitis MESHD encephalitis HP with MRI alterations (n=7). ADEM and LE cases showed a delayed onset compared to the other encephalitis MESHD encephalitis HP (p=0.001) and were associated with previous more severe COVID-19 respiratory involvement. Patients with MRI alterations exhibited worse response to treatment and final outcomes compared to other encephalitis MESHD encephalitis HP. Conclusions and relevance: We found a wide clinical spectrum of encephalitis MESHD encephalitis HP associated with COVID19 infection MESHD, underlying different pathophysiological mechanisms. Response to treatment and final outcome strongly depended on specific CNS-manifestations.

    nCoV-2019 infection MESHD induces neurological outcome and manifestation, linking its historical ancestor SARS-CoV & MERS-CoV: A systematic review and meta-analysis

    Authors: Ajay Prakash; Harvinder Singh; Phulen Sarma; Anusuya Bhattacharyya; Deba Prasad Dhibar; Neeraj Balaini; Ritu Shree; Manoj Goyal; Manish Modi; BIKASH MEDHI

    doi:10.21203/rs.3.rs-35790/v1 Date: 2020-06-15 Source: ResearchSquare

    Importance: The first systematic review and meta-analysis to help clinician to identify early the sign and symptoms MESHD of neurological manifestation in COVID-19 positive patients which further help in early management of patients. Objective: Present systematic review and meta-analysis aimed to discuss the prevalence SERO of neurological involvement of the 2019-nCoV patients and assess the symptomatic trend of events as compared to the 2002 “SARS” and 2012 “MERS” pandemics.Methods: The articles were systematically screened through several search engine and databases. The articles published or in preprint were included in the study till 15th May 2020. The systematic review done as per the published literatures which included 31 cross sectional, observational studies and case reports which revealed neural sign and symptoms MESHD in SARS-COV-2 disease MESHD. For meta-analysis, we included 09 observational and cross sectional studies which included COVID-19 positive patients and assessed the predominance of various neurological sign and symptoms MESHD in COVID-19 patients relation to SARS-2002 and MERS-2012. Data were analyzed by using the “MedCalc Statistical Software version 19.2.6 and reported as pooled prevalence SERO. Heterogeneity was investigated (standard I2 test).  Results: We have collected and screened about a total 2615 articles, finally we have included 31 articles for the systematic review and 09 for meta-analysis as per the inclusion/exclusion criteria. The analysis was made as per the prevalence SERO rate of neurological symptoms during the COVID-19 positive patients. The cumulative neurological outcome of SARS-2002 and MERS-2012 was assessed to get the trends which is next tried to correlate the events with the current pandemic. During the analysis severity and outcome of neurological manifestations range from simple headache MESHD headache HP to vague non-focal complaints to severe neurologic impairment associated with seizure MESHD seizure HP or meningitis MESHD meningitis HP.Conclusion & Relevance: Central and peripheral nervous system (CNS/PNS) manifestations were seen during the SARS-2002, MERS-2012 and COVID-19. However, none of the publication found with the primary or secondary objective of finding the neurological manifestation in the COVID-19 patients and their mechanism which strengthen the importance to start more precise clinical trials.

    Neurological Complications of COVID-19: A Systematic Review of Literature

    Authors: Shitiz Sriwastava; Samiksha Srivastava; Saurabh Kataria; Violina Melnic; Amelia Adcock; Zubeda Sheikh

    doi:10.21203/rs.3.rs-35507/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: To study the nature and frequency of occurrence of “significant” neurological complications in coronavirus disease MESHD-2019 (COVID-19) via a systematic review of the literature.Methods: We screened all articles resulting from a search of PubMed, Cochrane, Google Scholar and Scopus, using the keywords "COVID-19 and CNS", "SARS-CoV-2 and CNS”, “COVID-19 and neurological manifestation”, “SARS2 and neurological manifestation” and “COVID-19 and Brain” looking for reports of significant neurological manifestations that would potentially have an impact on the outcome.Results: Twenty-six articles met the inclusion criteria. The significant neurological diagnoses reported were stroke MESHD stroke HP, Guillain Barre Syndrome MESHD (GBS) and its variants, encephalitis MESHD encephalitis HP, seizures MESHD seizures HP, acute hemorrhagic necrotizing encephalopathy, acute HP acute disseminated encephalomyelitis MESHD (ADEM) and transverse myelitis MESHD myelitis HP. Although stroke MESHD stroke HP, predominantly ischemic, was observed in ~ 6% of COVID-19 patients from Wuhan, China, mortality in this cohort was 38%. Of the 24 pooled patients with reports of etiology, 17 had large vessel occlusions. GBS occurred in 5/1200 (0.4%) of the COVID-19 cohort from Italy. One of the six reported encephalitis MESHD encephalitis HP cases, the ADEM case and the report of transverse myelitis MESHD myelitis HP do not have data for conclusive diagnosis.Conclusion: The most frequent significant neurological association with COVID-19 is stroke MESHD stroke HP, predominantly ischemic. In a cohort from Wuhan, China, this was as frequent as ~ 6%, with a 38% mortality. Most common reported etiology is large vessel occlusion. Other reported significant neurological complications are GBS/variants, encephalitis MESHD encephalitis HP, seizures MESHD seizures HP and acute hemorrhagic necrotizing encephalopathy HP. The reports of ADEM and transverse myelitis MESHD myelitis HP lacked diagnostically conclusive data.

    Continuous Electroencephalography (cEEG) Characteristics and Acute Symptomatic Seizures HP Seizures MESHD in COVID-19 Patients

    Authors: Shreya Louis; Andrew Dhawan; Christopher Newey; Dileep Nair; Lara Jehi; Stephen Hantus; Vineet Punia

    doi:10.1101/2020.05.26.20114033 Date: 2020-05-28 Source: medRxiv

    Background: Neurological manifestations of COVID-19 have only recently been described, with a paucity of literature reporting the potential relationship between COVID-19 and acute symptomatic seizures HP seizures MESHD. Two prior studies found no clinical or electrographic seizures MESHD seizures HP in their cohorts of COVID-19 patients with altered mental status (AMS) and clinical seizure MESHD seizure HP-like events (SLEs). Methods: In this retrospective cohort study, 22 critically-ill COVID-19 patients above the age TRANS of 18 years who underwent EEG (electroencephalography) monitoring between April 20th, 2020 and May 20th, 2020 were studied. 19 patients underwent continuous EEG (cEEG) for at least 24 hours, and 3 patients underwent routine EEGs (<1 hour). Demographics including age TRANS, gender TRANS, comorbid medical, and neurological conditions were collected. Clinical variables included EEG findings, anti- seizure MESHD seizure HP medications, discharge disposition, and survival. Findings: 17 patients underwent EEG monitoring for unexplained altered mental status changes and 5 patients underwent monitoring for a seizure MESHD seizure HP-like event. 5 patients had epileptiform abnormalities on EEG HP (4 patients on cEEG, 1 on routine EEG); and only 2 of 5 epileptic EEG patients had a prior history of epilepsy MESHD. 2 patients in our cohort had electrographic seizures MESHD seizures in the absence HP in the absence of prior epilepsy MESHD history. No patients with epileptiform abnormalities or electrographic seizures MESHD seizures HP had acutely abnormal neuroimaging on CT or MRI. Interpretation: Encephalopathic COVID-19 positive patients had a range of EEG abnormalities HP, and a higher proportion of patients in this series had electrographic seizures MESHD seizures HP than previous literature suggests. This may be influenced by the duration of monitoring with cEEG and the use of a 21 channel electrode system. cEEG findings may help to guide antiseizure medical therapy, as well as the workup of altered mental status in the setting of unremarkable neuroimaging. Funding: No funding was used for this study.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.